Kexing Biopharm Partners with IQVIA for Global Clinical Development and Commercialization.

Kexing Biopharm has entered into a strategic partnership with IQVIA to accelerate the global development and commercialization of its innovative drugs and biosimilars, focusing on Europe and other regulated international markets. The partnership aims to leverage IQVIA's clinical research services and commercial insights to support Kexing's internationalization efforts. Kexing has already achieved rapid approval and launch for its in-licensed nab-paclitaxel in several key jurisdictions.

Kexing Biopharm (688136.SH), a leading biopharmaceutical enterprise, has entered into a strategic partnership with IQVIA (NYSE:IQV), a global leader in clinical research services, commercial insights, and healthcare intelligence. This alliance aims to accelerate the global clinical development, regulatory approval, and commercialization of Kexing's innovative drugs and biosimilars, with a strategic focus on Europe and other regulated international markets [1][2].

The partnership leverages IQVIA's deep expertise in global clinical trial design, regulatory strategy, and data-driven insights. By combining Kexing's innovative product pipeline with IQVIA's global operational infrastructure, the two companies aim to enhance trial efficiency and enable faster access to international markets. This collaboration is expected to significantly strengthen Kexing's global development capabilities and accelerate its transition toward becoming an international biopharmaceutical innovator [1][2].

Kexing Biopharm has already achieved rapid approval and launch for its in-licensed nab-paclitaxel in several key jurisdictions. The company's R&D pipeline is rapidly advancing, focusing on therapeutic areas such as antivirus, antitumor, immunosuppressant, and metabolic diseases. The partnership with IQVIA reflects Kexing's long-term commitment to international expansion through scientific rigor, efficient execution, and strong partnerships [1][2].

During the signing ceremony, Mr. Brian Mi, President of IQVIA Asia Pacific, highlighted Kexing's rapid progress in overseas commercialization and product innovation, stating that the collaboration would unlock new opportunities for both parties. Mr. Yanqing Zhao, CEO of Kexing Biopharm, emphasized that IQVIA's global clinical data resources, patient insights, and regulatory knowledge will play a critical role in optimizing development strategy, improving success rates, and accelerating global registration timelines [1][2].

References:
[1] https://www.prnewswire.com/news-releases/kexing-biopharm-enters-strategic-partnership-with-iqvia-to-accelerate-global-expansion-302526319.html
[2] https://www.prnewswire.co.uk/news-releases/kexing-biopharm-enters-strategic-partnership-with-iqvia-to-accelerate-global-expansion-302526319.html